Home / 2019 / August / 06

Daily Archives: August 6, 2019

The Art of Science: Olympus Launches the First Global Image of the Year Award

Prizes to be awarded to top global and regional submissions

WALTHAM, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) — Inspired by the beauty and breadth of images submitted for the 2018 Image of the Year Life Science Light Microscopy Award held in Europe, Olympus has launched its first Global Image of the Year Life Science Light Microscopy Award, recognizing the best in life science imaging worldwide. Participants can win a CX43 microscope with a DP27 digital camera, X Line objectives, or an OM-D E-M5 Mark II camera.

Those interested in participating can enter through Jan. 31, 2020 by uploading images at Olympus-LifeScience.com/IOTY. Winners will be selected by a jury panel and announced in March 2020.

The jury consists of global representatives from both science and the arts, including photographer Ron Caplain; Geoff Williams, a bioimaging facility manager at Brown University; Urs Ziegler, the head of a microscopy imaging facility at the University of Zurich; Stefan Terjung, the operational manager of an advanced light microscopy facility at EMBL Heidelberg; Hiroaki Misono, a graduate school professor of brain science at Doshisha University; Zhu Xueliang, a professor at the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; Yalin Wang, Director of Biomedical Research Core Facilities at Westlake University, Hangzhou, China; and Wendy Salmon, a light microscopy specialist of a bioimaging facility at MIT.

Participants may upload up to three microscopy images, accompanied by a brief explanation of the equipment used. All entries will be evaluated based on artistic and visual aspects, scientific impact, and microscope proficiency. Regional prizes in Asia, Europe, and the Americas will be awarded in addition to the global prize.

The Image of the Year European Life Science Light Microscopy Award began in 2017 to celebrate both the artistic and scientific value of microscopy images. Now on a global scale, the competition aims to encourage people to look at scientific images in a new way, appreciate their beauty, and share images with others.

More information about the Global Image of the Year Life Science Light Microscopy Award, including jury members’ biographies, last year’s winning images, and the full terms and conditions, can be found at Olympus-LifeScience.com/IOTY.

Olympus is a registered trademark and X Line is a trademark of Olympus Corporation.

Media Contact:
Kristin Schaeffer
(610) 973-2400
kristin@klunkmillan.com

PaybyPhone Announces Yuru Wang As Vice President Of Software Development

VANCOUVER, British Columbia, Aug. 06, 2019 (GLOBE NEWSWIRE) — PayByPhone, the global leader in mobile parking payments, today announced that Yuru Wang has been named Vice President of Software Development.  An experienced technology and software development leader, Wang joins PayByPhone from SAP, where he was Vice President of Engineering.  In his new position, Wang will oversee software development for PayByPhone’s global operations.

“PayByPhone is on an exciting growth trajectory, and Yuru Wang will be a fantastic addition to help achieve that growth,” said Andy Gruber, PayByPhone’s CEO.  “Yuru brings a wealth of experience in software development and in scaling companies quickly.  His experience will be vital as we continue to innovate as an organization, launching industry-leading solutions to make people’s journeys easier.”

Yuru brings with him over two decades of experience in software development and holds a master’s in computer science from the University of Saskatchewan.  He has a proven track record of building and scaling successful technology teams and while navigating through fast organizational growth.  In addition to leading the software development strategy for PayByPhone, Wang will be responsible for overseeing the expansion of the technology and information teams.

“I’m thrilled to be joining the company during such an exciting time of growth,” said Wang.  “PayByPhone is at an energizing point in their journey with seemingly limitless potential in front of them. I look forward to building great products together and delivering innovative solutions to mobility.”

About PayByPhone

PayByPhone is one of the fastest growing mobile payment companies in the world, processing over 100 million transactions totaling more than $400 million USD in payments annually. Through the company’s mobile web, smartphone and smartwatch applications, PayByPhone helps millions of consumers easily and securely pay for parking without the hassles of waiting in line, having to carry change or risking costly fines. A subsidiary of Volkswagen Financial Services AG, PayByPhone is leading the way in the creation of the mobile future.

Media Contact
Erica England
Director of Media Relations, Arketi Group
eengland@arketi.com

Seoul National University Hospital and Syapse Sign Multi-Year Renewal Agreement to Expand Access to Precision Medicine in South Korea

Syapse and SNUH will work together to build Asia’s first learning health network of real-world data derived from the region’s leading precision oncology hospitals

Co-hosted symposium of East Asian hospitals will share best practices and strategies to accelerate precision medicine adoption in the region

SAN FRANCISCO and SEOUL, South Korea, Aug. 06, 2019 (GLOBE NEWSWIRE) — Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), the premier hospital in South Korea, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data sharing network for leading precision oncology hospitals in the region.

“We are very pleased to enter into this expanded multi-year agreement with Syapse focused on accelerating the practice of precision medicine,” said Kyung Hwan Kim, M.D., Ph.D., Chief Information Officer at Seoul National University Hospital. “We are proud of the progress we have made together and look forward to continuing our efforts with Syapse to develop the leading precision medicine platform in South Korea and the Asia Pacific region.”

As the leading cancer hospital in South Korea, SNUH has built a global reputation for innovative approaches to cancer care. SNUH serves more than 8,000 cancer patients per year across 16 Cancer Specialty Centers, 10 Multidisciplinary Cancer Treatment Centers, and a Cancer Clinical Trials Center. The Syapse and SNUH collaboration, established in January 2018, has focused on scaling the delivery of precision medicine insights through the integration and curation of clinical, molecular testing and outcomes data collected in information systems including electronic health records (EHRs).

“As a pioneer in cancer care and technology, SNUH is an important global leader in precision medicine and we are honored to expand our collaboration focused on delivering better outcomes for cancer patients in South Korea,” said Ken Tarkoff, CEO, Syapse. “Together we will work to build a precision medicine data sharing network in the region that will provide the high-quality real-world data and insights required to support hospitals in delivering the most informed personalized care to every cancer patient.”

SNUH and Syapse have also announced today that they will co-host the Syapse Precision Medicine Council Asia with support from MegazoneCloud. The inaugural invitation-only symposium for Syapse partners will be held at SNUH in Seoul on November 22 and 23, 2019 and convene clinical and executive healthcare leaders who are dedicated to advancing precision oncology. The Precision Medicine Council is focused on three primary goals: sharing best practices in growing precision medicine programs, generating actionable insights to advance the industry as a whole, and building upon current data-sharing initiatives.

“We are pleased to partner with Syapse to co-host the inaugural Precision Medicine Council Asia and look forward to welcoming our esteemed colleagues from across the region to South Korea. Together, we will provide the leadership necessary to support hospitals across East Asia in building world-class precision medicine programs,” added Dr. Kim.

About Seoul National University Hospital
Seoul National University Hospital has been leading the development of medicine and safeguarding public health in Korea over the past 100 years. It was established in 1885 as Korea’s first national hospital under the name Je Jung Won. Later, it became the affiliate hospital for Seoul National University College of Medicine before being recognized as a special corporate body under the name of Seoul National University Hospital. Today, the hospital is a world class center comprised of the Main Hospital, the Children’s Hospital, the Cancer Hospital and the Biomedical Research Institute. With over 1,700 hospital beds, approximately 2,000 inpatients and 8,000 outpatients are treated each day by 533 medical professors and 5,800 staff. Seoul National University Hospital’s vision for the 21st century is based on patient-oriented care, respect for humankind, the creation of knowledge and public service.

About Syapse
Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our insights platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we have built one of the world’s largest learning health networks of provider-driven precision medicine data. In collaboration with our partners — including Advocate Aurora Health Care, CommonSpirit Health, Henry Ford Health System, Providence St. Joseph Health, and Seoul National University Hospital — we are working toward a future in which all cancer patients have access to the best personalized care.

About MegazoneCloud
MegazoneCloud is a cloud-specialized IT company providing end-to-end cloud services from infrastructure, platform, application and data services. MegazoneCloud is the first Premier Consulting Partner of Amazon Web Services in Korea as well as the number one AWS partner in Asia. MegazoneCloud is a business partner of Syapse in Korea providing cloud data services to the healthcare industry.

Media Contact
Colin Sanford for Syapse at colin.sanford@syapse.com

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

 Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines

LONDON and WASHINGTON, Aug. 06, 2019 (GLOBE NEWSWIRE) — GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. All three cause hemorrhagic fever with subsequent death in an average of 50 percent of cases.1,2 More than 1,600 people have already died during the ongoing Ebola Zaire outbreak in the Democratic Republic of Congo (DRC),3 leading the World Health Organization (WHO) to recently declare it a Public Health Emergency of International Concern.4

Under the agreements between GSK and Sabin, Sabin has exclusively licensed the technology for all three candidate vaccines and acquired certain patent rights specific to these vaccines. The three candidate vaccines were initially developed collaboratively by the U.S. National Institutes of Health and Okairos, which was acquired by GSK in 2013. The candidate vaccines, based on GSK’s proprietary ChAd3 platform, were further developed by GSK, including the Phase II development for the Ebola Zaire vaccine.

Sabin Chief Executive Officer Amy Finan commented, “As an organization committed to improving lives through immunization, Sabin is dedicated to preventing devastating outbreaks of the Ebola and Marburg viruses. Thanks to GSK’s longstanding engagement in global health, as well as its scientific expertise, the ChAd3 vaccine program is well positioned to be an effective weapon in the global community’s arsenal against Ebola. Sabin appreciates GSK’s years of work to advance the ChAd3 Ebola program and the productive partnership the two organizations have established. Sabin plans to continue the development and seek regulatory approval of Ebola and Marburg vaccines with our shared goal of making them available to the millions of people potentially at risk.”

Thomas Breuer, Chief Medical Officer of GSK Vaccines, said: “These agreements with the Sabin Vaccine Institute are an important next step in the fight against Ebola and Marburg viruses. Enabling Sabin to build on the scientific progress GSK has delivered up to Phase II increases the likelihood these candidate vaccines may help prevent potential future outbreaks, and exemplifies GSK’s approach to global health vaccines which supports partners in taking forward our innovations in a sustainable way. I am proud of the work that our world-leading vaccines scientists at GSK have contributed so far to the development of these vaccine candidates, including the Ebola Zaire candidate vaccine which has demonstrated encouraging results in studies to date.”

To further develop the ChAd3 Ebola and Marburg vaccines, Sabin has entered into a Research Collaboration Agreement with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID). The ChAd3-based vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses have demonstrated a strong safety profile and encouraging immunogenicity results after being administered to more than 5,000 adults and 600 children, in 13 different clinical trials to date.

Specifically, the majority of the clinical volunteers were tested using the ChAd3 Ebola Zaire vaccine. In addition to numerous Phase I trials, the Ebola Zaire vaccine has been tested in three Phase II trials in Africa; two trials were conducted by GSK and one was conducted by the Partnership for Research on Ebola Virus in Liberia (PREVAIL), a clinical research partnership between NIAID and the Liberian Ministry of Health. The Ebola Sudan vaccine has been evaluated in three Phase I trials in Africa and the United States as a bivalent formulation with Ebola Zaire and will be evaluated in an upcoming Phase I study as monovalent formulation. A Phase I study of the Marburg vaccine is ongoing in the United States.

About the Sabin Vaccine Institute
The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin’s R&D strategy focuses on continuing the development of candidate vaccines that have demonstrated early scientific value and target disease primarily impacting the world’s most vulnerable populations, but have little commercial value. The Blavatnik Family Foundation and the David E.I. Pyott Foundation provided seed funding to launch Sabin’s ChAd3 Ebola program. In past years, Sabin received more than $110 million for vaccine R&D programs from public and philanthropic funding sources, including the Bill & Melinda Gates Foundation, European Commission, Dutch Ministry of Foreign Affairs, Global Health Innovative Technology Fund and the Michelson Medical Research Foundation.

Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About GSK
GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the world’s leading vaccine company, with a portfolio that helps protect people throughout life and an innovative pipeline of 16 vaccines in development. Our vaccines help prevent illnesses such as hepatitis A and B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, pneumococcal disease, influenza, rotavirus, shingles and meningitis. At GSK, more than 17,000 people worldwide deliver around two million vaccine doses per day to people in 158 countries. For further information, please visit www.gsk.com.

About Ebola Zaire, Ebola Sudan and Marburg
Ebola Zaire, Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses. All can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of the hemorrhagic fevers caused by filoviruses has been licensed to date.

The 2014-2016 outbreak in West Africa, the largest Ebola outbreak in history, was caused by Ebola Zaire, starting in Guinea and then moving across land borders to Sierra Leone and Liberia. The outbreak eventually spread to 10 countries and took the lives of more than 11,000 people. The ongoing 2018-2019 outbreak in eastern DRC is also caused by Ebola Zaire and has claimed the lives of more than 1,600 people. The outbreak has been further complicated by significant security issues adversely affecting public health response activities, and on July 17, WHO declared it a Public Health Emergency of International Concern.

Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when a number of laboratory workers, including some in Marburg, Germany, developed hemorrhagic fever. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

 

GSK enquiries:

UK Media enquiries: Simon Steel +44 (0) 20 8047 5502 (London)
Simon Moore +44 (0) 20 8047 5502 (London)
US Media enquiries: Evan Berland +1 215 751 5497 (Philadelphia)
Sean Clements +1-215-751-3565 (Philadelphia)
   
Analyst/Investor enquiries: Sarah Elton-Farr +44 (0) 208 047 5194 (London)
Danielle Smith +44 (0) 20 8047 7562 (London)
James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Sabin Vaccine Institute Matthew Fitzgerald +1 617 939 8314 (Washington DC)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Principal risks and uncertainties’ in the company’s Annual Report on Form 20-F for 2018.
Registered in England & Wales:
No. 3888792
 
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

1 WHO fact sheet, Ebola virus disease, accessed 30 July 2019 – available at: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease

2 WHO fact sheet, Marburg virus disease, accessed 30 July 2019 – available at: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease

3 WHO, Ebola in the Democratic Republic of the Congo – Health Emergency Update, accessed 30 July 2019 – available at: https://www.who.int/emergencies/diseases/ebola/drc-2019

4 WHO press release, Ebola outbreak in the Democratic Republic of the Congo declared a Public Health Emergency of International Concern, 17 July 2019 – available at: https://www.who.int/news-room/detail/17-07-2019-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-a-public-health-emergency-of-international-concern

BNM likely to cut interest rate in next 3-6 months – economist

KUALA LUMPUR, Bank Negara Malaysia (BNM) may cut its key interest rate in the next three to six months, partly because the world economy has worsened following the escalating United States (US)-China trade dispute, said CIMB Group chief economist Dr Donald Hanna.

He said there was about a 60 per cent chance of another rate cut, unfortunately, on the back of the likely increase in tariffs on Chinese products in September by the US, which was an external blow to an open economy like Malaysia.

The next three to six months, he said, would also depend on the US Federal Reserve’s plan on its interest rate policy and impact of the US tariff on Chinese products.

“Other Asian central banks will soon follow the policy direction of US interest rates movement,” he told reporters after the ASEAN+3 Regional Economic Outlook 2019 Roadshow here, today.

In May this year, BNM reduced the overnight policy rate to three per cent from 3.25 per cent previously, the first time it has cut the rate since July 2016.

Previously, US President Donald Trump said he will impose a 10 per cent tariffs on another US$300 billion (US$1=RM4.18) of Chinese-made products starting Sept 1, which would effectively put a tax on all Chinese goods coming into the US.

Source: BERNAMA (News Agency)

Airbus Malaysia confident of hitting US$500 mln contribution to GDP in 5 years

KUALA LUMPUR, Airbus Malaysia is confident that it is on track to reach the US$550 million target contribution to the country’s gross domestic product (GDP) in five years’ time.

Its vice-president and country head, Raymond Lim said currently the contribution is at 30 per cent of the target amount.

The target includes some of the activities that we have not revealed yet. As time goes by, we will reveal them.

Malaysia has been an important market due to the support given by the government, including incentives for aerospace companies, he told the media at the opening of the new regional helicopter completion and delivery centre (CDC), which was opened by Transport Minister Anthony Loke Siew Fook, here today.

Lim said Malaysia is blessed with a talent pool which makes a good addition for the industry to grow.

On the CDC, Lim said it expects to deliver 13 helicopters in 2020.

This year, the company aims to deliver seven helicopters with four already handed over.

The CDC has the full capacity of completing and delivering up to 20 helicopters a year.

We are always ready to ramp-up to full capacity. And we need to ensure that we ramp up accordingly with regards to the rate of competency, with improvements, with the right skill sets in order to grow into full steam, said Lim.

He said Airbus Malaysia’s customers vary in different markets that Airbus supports, including parapublics, oil and gas, as well as private owners, with the majority being foreign customers.

Located in Subang, the new CDC would see new helicopters for customers in the Southeast Asian region being completed in, and delivered from the centre — consolidating Malaysia’s role as the Airbus regional hub for helicopters services, customer support and full flight simulator training.

Meanwhile, Loke said Subang would receive a huge strategic investment in aerospace, which would be announced soon.

However, he did not reveal its details.

Recently, Selangor Menteri Besar Amirudin Shari said plans are afoot to rejuvenate Subang as a new economic attraction in the state.

Subang has been named as one of Selangor’s three aviation areas, with the others being Serendah and Sepang.

Currently, 200 aerospace-related companies are situated in the areas with Selangor now becoming home to 62 per cent of the Malaysian aviation industry.

The state is also optimistic of increasing its market share in the local aerospace industry to 70 per cent by 2020.

Source: BERNAMA (News Agency)

MBSB Bank launches ‘The Journey 2.0″ campaign

KUALA LUMPUR, MBSB Bank has launched its ‘The Journey 2.0’ campaign to recognise the contributions of its loyal customers.

The launch was inaugurated here by MBSB Bank president and chief executive officer Datuk Seri Ahmad Zaini Othman.

The campaign is open to customers who subscribe to at least two of the following products — Personal Financing-i, Property Financing-i, Equipment Financing-i, Wealth Management products, CASA-i, Term Deposit-i, and Online Journey Individual.

Campaign participants stand to win an umrah package for two or a trip for two to Egypt and Jordan, to the Balkans or to Dubai.

Ahmad Zaini expressed hope the campaign would not only retain existing customers but also attract new ones.

The campaign period is from June 1, 2019 to May 31,2020.

Source: BERNAMA (News Agency)